Biology subjects

Bogdani, M.

Publications and source records attributed to Bogdani, M..

4 recordsLinked to original sources

bioRxiv2026

Digital Atlases to Unlock the Potential of Brain Biorepository Tissues for Interdisciplinary Research

Human brain tissue preserved in biorepositories is foundational for the structural, cellular, and biomolecular research necessary for a mechanistic understanding of neurological diseases. Realizing the research potential of these valuable resources requires well-characterized research-relevant tissue that can be efficiently identified by investigators and incorporated into the conceptual and computational frameworks of interdisciplinary research. Several large-scale efforts to improve research reliability and reproducibility have sought to characterize and annotate the processes by which these samples are collected, yet limited progress has been made on standardizing spatial information for these samples. Biorepositories systematically collect brain tissue according to a brain sampling protocol (BSP) that differs between institutions, yet explicit spatial information regarding the samples may not be documented in standard operating procedures (SOPs). The amount of anatomical location details available to investigators are inconsistent across biorepositories and typically lack sufficient anatomical precision to ensure correspondence with samples from other biorepositories or research relevant brain regions specified by neuroimaging, functional, or disease-susceptibility criteria. Here, we introduce a pipeline for developing a Spatial Atlas for Mapping Protocol Locations of Ex vivo Samples (SAMPLES), which uses a neuroimaging framework to create a 3D representation of a BSP through a metrically precise digital instantiation of the procedures for brain extraction, segmentation, slicing, and sampling on a modern digital brain template. SAMPLES incorporates modern neuroinformatics conventions to create explicit 3D labels of BSP-defined samples that can be interactively visualized with freely available neuroimaging software. We illustrate the pipeline by developing an atlas for the protocol from the University of Washington BioRepository and Integrated Neuropathology laboratory (UW BRaIN SAMPLES). By providing an explicit, computable reference, SAMPLES atlases can support the efficient identification, referencing, and utilization of postmortem samples for interdisciplinary research. These capabilities enable biorepository workflows, data harmonization across biorepositories, and integration with antemortem neuroimaging.

neuroscience↗

bioRxiv2024

Tau filaments with the Alzheimer fold in cases with MAPT mutations V337M and R406W

Frontotemporal dementia (FTD) and Alzheimers disease are the most common forms of early-onset dementia. Dominantly inherited mutations in MAPT, the microtubule-associated protein tau gene, cause FTD and parkinsonism linked to chromosome 17 (FTDP-17). Individuals with FTDP-17 develop abundant filamentous tau inclusions in brain cells. Here we used electron cryo-microscopy to determine the structures of tau filaments from the brains of individuals with MAPT mutations V337M and R406W. Both mutations gave rise to tau filaments with the Alzheimer fold, which consisted of paired helical filaments in all V337M and R406W cases and of straight filaments in two V337M cases. We also identified a new assembly of the Alzheimer fold into triple tau filaments in a V337M case. Filaments assembled from recombinant tau(297-391) with mutation V337M had the Alzheimer fold and showed an increased rate of assembly.

biophysics↗

bioRxiv2023

Inhibition of hyaluronan synthesis prevents β-cell loss in obesity-associated type 2 diabetes

Pancreatic {beta}-cell dysfunction and death are central to the pathogenesis of type 2 diabetes (T2D). We have identified a novel role for the inflammatory extracellular matrix polymer hyaluronan (HA) in this pathophysiology. Low levels of HA are present in healthy pancreatic islets. However, HA substantially accumulates in cadaveric islets of human T2D and islets of the db/db mouse model of T2D in response to hyperglycemia. Treatment with 4-methylumbelliferone (4-MU), an inhibitor of HA synthesis, or the deletion of the major HA receptor CD44, preserve glycemic control and insulin levels in db/db mice despite ongoing weight gain, indicating a critical role for this pathway in T2D pathogenesis. 4-MU treatment and the deletion of CD44 likewise preserve glycemic control in other settings of {beta}-cell injury including streptozotocin treatment and islet transplantation. Mechanistically, we find that 4-MU increases the expression of the apoptosis inhibitor survivin, a downstream transcriptional target of CD44 dependent on HA/CD44 signaling, on {beta}-cells such that caspase 3 activation does not result in {beta}-cell apoptosis. These data indicate a role for HA accumulation in diabetes pathogenesis and suggest that it may be a viable target to ameliorate {beta}-cell loss in T2D. These data are particularly exciting, because 4-MU is already an approved drug (also known as hymecromone), which could accelerate translation of these findings to clinical studies.

immunology↗

bioRxiv2019

Regulatory T cell expansion by a highly CD25-dependent IL-2 mutein arrests ongoing autoimmunity

Interleukin-2 (IL-2) controls the homeostasis and function of regulatory T cells (Tregs) and defects in the IL-2 pathway contribute to multiple autoimmune diseases. Although recombinant IL-2 therapy has been efficacious in certain inflammatory conditions, the capacity for IL-2 to also activate inflammatory effector responses highlights the need for IL-2-based therapeutics with improved Treg-specificity. From a panel of rationally designed IL-2 variants, we identified IL-2 muteins with reduced potency and enhanced Treg-selectivity due to increased dependence on the IL-2-receptor component CD25. As an Fc-fused homodimer, the optimal Fc.IL-2 mutein induced selective Treg enrichment and reduced agonism of effector cells across a wide dose range. Furthermore, despite being a weaker agonist, overall Treg growth was greater and more sustained due to reduced receptor-mediated clearance of the Fc.IL-2 mutein compared to Fc-fused wild-type IL-2. Preferential Treg enrichment was also observed in the presence of activated pathogenic T cells in the autoimmune target organ, despite a loss of Treg-selectivity in an IL-2R-proximal response. These features allowed for extended resolution of spontaneous autoimmunity using infrequent dosing schedules. Thus, IL-2 muteins enable efficient, flexible, and targeted control of the autoimmune response. One Sentence SummaryA CD25-dependent IL-2 mutein selectively expands regulatory T cells and provides potent and targeted control of autoimmunity.

immunology↗